Homemarket Newsstocks News

    Advanced Enzyme jumps most in 7 months after Nalanda India Fund ups stake

    Advanced Enzyme jumps most in 7 months after Nalanda India Fund ups stake

    Advanced Enzyme jumps most in 7 months after Nalanda India Fund ups stake
    Read Time
    2 Min(s) Read
    Profile image

    By CNBCTV18.com  IST (Updated)


    Advanced Enzyme Technologies is the top gainer on the Nifty 500 index but the stock still trades lower on a year-to-date basis.

    Shares of enzymes manufacturer Advanced Enzyme Technologies Ltd. jumped the most since February this year after Nalanda India Equity Fund increased its stake in the company. The fund acquired a 2.6 percent stake or 29 lakh shares in the company through a large trade on Monday, showed data from the exchanges.
    The sellers in this transaction were the company's promoters, who sold 25.7 lakh shares or 2.5 percent of the total equity. As of the quarter ended June, promoters held a 52.7 percent stake in the company.
    Nalanda India Equity Fund has been consistently increasing its stake in the company as evident from the data. As of the June quarter, the fund held a 6.2 percent stake in the company worth nearly Rs 200 crore. It had increased its stake in the March quarter this year to 6.1 percent from 4.7 percent last year.
    CNBC TV-18 highlighted the large trade in the company during its dealing room chatter on Monday. Dealers had suggested that the promoter entity was the seller in the large trade.
    Advanced Enzyme is a market leader in the manufacturing of enzymes and probiotics. The largest Indian Enzyme company is engaged in the research, development, manufacturing, and marketing of over 400 proprietary products. At the end of FY22, the Human Nutrition business was the biggest revenue contributor at 68 percent, followed by Bio Processing and Specialized Manufacturing.
    India and America are the two core markets of the company, who together contribute 84 percent of the overall revenue.
    For the April-June period of the current financial year, the company's revenue declined 12 percent year-on-year, led by a de-growth in its core business. ICICI Direct expects the business environment to improve from the second half of FY23. It downgraded the stock to "reduce" from "hold" as it awaits normalcy to return in its core business of Human Nutrition and a better margin profile.
    Shares of Advanced Enzyme Technologies are trading 13.3 percent higher at Rs 302.50 as of 10 AM.
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    arrow down

      Most Read

      Market Movers

      View All